NCT01636622View on ClinicalTrials.gov

Study of Vemurafenib, Carboplatin, and Paclitaxel

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 9, 2012

Primary Completion Date

April 21, 2020

Study Completion Date

April 21, 2020

Conditions
Advanced Cancers
Interventions
DRUG

Vemurafenib

Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle.

DRUG

Carboplatin

Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.

DRUG

Paclitaxel

Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01636622 - Study of Vemurafenib, Carboplatin, and Paclitaxel | Biotech Hunter | Biotech Hunter